Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES Databases
NCT06077045 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12775880
Last updated 2025-04-27
Summary
In 2013, the NHS started a vaccination program in some regions of England to provide free flu vaccines to children aged 2 years or older, and younger than 16 years. The program has since been rolled out across England. Most children are given a vaccine that is sprayed into their nose. In clinical trials, this vaccine has been shown to protect children from experiencing severe flu symptoms. It is important to describe how it is used, and what happens to children who receive it in the wider community. This evidence will help the NHS to check that the vaccine roll out runs as planned and produces the intended benefits.
This study aims to: (1) describe how many children each year receive flu vaccines, and describe the characteristics of children who are and aren't vaccinated for influenza; (2) test how often children receiving the vaccine see their GP or a hospital doctor for symptoms related to flu, compared to those who don't; and (3) to test what groups of children are more or less likely to receive a flu vaccine. To answer these objectives, the study will use the Clinical Practice Research Datalink, linked to Hospital Episode Statistics and the Office for National Statistics database.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 0 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-18
- Primary Completion
- 2023-07-04
- Completion
- 2023-07-04
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).
NCT02143882 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls
NCT03104790 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study
NCT03502291 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia
NCT02972957 ·Status: COMPLETED ·Phase: PHASE4
-
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
NCT02967393 ·Status: COMPLETED ·Phase: PHASE4
-
Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014
NCT01764269 ·Status: COMPLETED ·Phase: NA
-
Childhood Influenza Immunisation in General Practice Invitation Trial
NCT02921633 ·Status: COMPLETED ·Phase: NA
-
Influenza Vaccine in Children With Asthma
NCT04086628 ·Status: UNKNOWN
-
Safety of LAIV4 in Children With Asthma
NCT03600428 ·Status: COMPLETED ·Phase: PHASE4
-
Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE 2 Study
NCT02111512 ·Status: COMPLETED ·Phase: PHASE4
-
Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age
NCT03020472 ·Status: TERMINATED ·Phase: PHASE4
-
Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants
NCT01194297 ·Status: TERMINATED ·Phase: PHASE4
-
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
NCT01439360 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
NCT01246999 ·Status: COMPLETED ·Phase: PHASE4
-
Development of Childhood Anti-Influenza Immunity
NCT03673345 ·Status: COMPLETED ·Phase: PHASE4
-
Study of a Flu Vaccine in Children
NCT00001127 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old
NCT01992107 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
NCT07133802 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345
NCT01702454 ·Status: COMPLETED ·Phase: PHASE3
-
Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine
NCT07232745 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population
NCT00700193 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
NCT03300050 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
NCT00980005 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months
NCT00311428 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Quadrivalent Influenza Vaccine Among Children
NCT01240746 ·Status: COMPLETED ·Phase: PHASE3